Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27 (PLATO-dose)
This study is currently recruiting participants.
Verified January 2012 by Les Laboratoires des Médicaments Stériles
Study NCT01509365   Information provided by Les Laboratoires des Médicaments Stériles

First Received on January 9, 2012.   Last Updated on January 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiovascular Disease
Overweight
Additional conditions recognized in this trial
Cardiovascular Diseases
Coronary Artery Disease
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Body Weight
Coronary Disease
Heart Diseases
Myocardial Ischemia
Signs and Symptoms
Vascular Diseases
Interventions listed in this trial
clopidogrel
Additional drug interventions recognized in this trial
Platelet Aggregation Inhibitors
Ticlopidine
More general drug interventions related to this trial
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P2 Receptor Antagonists
Purinergic P2Y Receptor Antagonists
Therapeutic Uses
Sponsors listed in this trial
Les Laboratoires des Médicaments Stériles
University Hospital Fattouma Bourguiba


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services